AIMS: To determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters. METHODS: Clinicopathological data were collected from 58 patients with ESCC who underwent oesophagectomy and had no prior radiotherapy or chemotherapy. Immunostaining was performed on the primary tumours. Expression of Fas was correlated with patients' demographics, tumour characteristics and stage, R category of surgery, and patients' survival. RESULTS: The actuarial survival rates of all patients at two and five years after surgery were 48% and 14%, respectively. Fas expression was detected in 89.7% of ESCCs. Higher Fas expression recorded on a four point scale correlated with better tumour differentiation (p < 0.01), but not with other patient or tumour variables. Importantly, higher Fas expression was associated with better survival (p = 0.0317). CONCLUSIONS: These findings suggest that Fas activated apoptosis is important in the pathogenesis of ESCC. This molecular pathway may be a potential therapeutic target for ESCC.
AIMS: To determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters. METHODS: Clinicopathological data were collected from 58 patients with ESCC who underwent oesophagectomy and had no prior radiotherapy or chemotherapy. Immunostaining was performed on the primary tumours. Expression of Fas was correlated with patients' demographics, tumour characteristics and stage, R category of surgery, and patients' survival. RESULTS: The actuarial survival rates of all patients at two and five years after surgery were 48% and 14%, respectively. Fas expression was detected in 89.7% of ESCCs. Higher Fas expression recorded on a four point scale correlated with better tumour differentiation (p < 0.01), but not with other patient or tumour variables. Importantly, higher Fas expression was associated with better survival (p = 0.0317). CONCLUSIONS: These findings suggest that Fas activated apoptosis is important in the pathogenesis of ESCC. This molecular pathway may be a potential therapeutic target for ESCC.
Authors: D Kägi; F Vignaux; B Ledermann; K Bürki; V Depraetere; S Nagata; H Hengartner; P Golstein Journal: Science Date: 1994-07-22 Impact factor: 47.728
Authors: Simon Law; Dora L W Kwong; Ka-Fai Kwok; Kam-Ho Wong; Kent-Man Chu; Jonathan S T Sham; John Wong Journal: Ann Surg Date: 2003-09 Impact factor: 12.969
Authors: Remco van Doorn; Remco Dijkman; Maarten H Vermeer; Theo M Starink; Rein Willemze; Cornelis P Tensen Journal: Cancer Res Date: 2002-10-01 Impact factor: 12.701
Authors: Bernd Kubista; Florian Klinglmueller; Martin Bilban; Martin Pfeiffer; Richard Lass; Alexander Giurea; Phillipp T Funovics; Cyril Toma; Martin Dominkus; Rainer Kotz; Theresia Thalhammer; Klemens Trieb; Teresa Zettl; Christian F Singer Journal: Int Orthop Date: 2010-03-26 Impact factor: 3.075
Authors: K Enomoto; M Sho; K Wakatsuki; T Takayama; S Matsumoto; S Nakamura; T Akahori; T Tanaka; K Migita; M Ito; Y Nakajima Journal: Clin Exp Immunol Date: 2012-05 Impact factor: 4.330
Authors: M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi Journal: Cell Death Differ Date: 2015-02-06 Impact factor: 15.828